CTIS2023-508840-22-00招募中1 期
A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy - CLNP023F12301
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male and female patients = 18 years of age with evidence of active thrombotic microangiopathy (TMA), including thrombocytopenia, evidence of hemolysis, and kidney injury, based on the following laboratory findings: • Platelet count <150x109/L during the Screening Period, and • LDH =1.5 x upper limit of normal (ULN) during the Screening Period and hemoglobin = lower limit of normal (LLN) for age and gender during the Screening Period, and • Serum creatinine =ULN during the Screening Period with acute worsening of kidney function. (Patients requiring dialysis for acute kidney injury are eligible)., Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections is required prior to the start of study treatment. If the patient has not been previously vaccinated, or if a booster is required, vaccine should be given according to local regulations, at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination or before vaccination is given, prophylactic antibiotic treatment must be administered at the start of study treatment and for at least 2 weeks after vaccination., If not received previously, vaccination against Haemophilus influenzae infection should be given if available and according to local regulations. The vaccine should be given at least 2 weeks prior to first study drug administration., Among patients with a kidney transplant, (a) known history of aHUS prior to current kidney transplantation, or (b) If no history of aHUS prior to the current transplantation is available, patients may be eligible without changes of immunosuppressive regimen if investigator excludes other causes of TMA not attributable to aHUS, especially transplant rejection. If immunosuppressive regimens (e.g., calcineurin inhibitor [CNI] or mammalian target of rapamycin inhibitor [mTORi] need to be modified after transplantation, evidence that TMA has persisted for at least 4 days after modification needs to be available.
排除标准
- •Previous or ongoing treatment with complement inhibitors, including anti-C5 antibody., Systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), or antiphospholipid antibody positivity or syndrome., Chronic hemo- or peritoneal dialysis., Any adenoviral COVID-19 vaccine within 28 days prior to screening visit., A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency, and/or Shiga toxin-related hemolytic uremic syndrome (STX-HUS), and/or positive direct Coombs test., Identified drug exposure-related HUS or HUS related to known genetic defects of cobalamin C metabolism or known diacylglycerol kinase e (DGKE) mediated aHUS., Started receiving PE/PI 14 days or longer before the start of screening visit for the current TMA., Bone marrow transplantation (BMT)/hematopoietic stem cell transplantation (HSCT), heart, lung, small bowel, pancreas, or liver transplantation., In patients with a kidney transplant, acute kidney dysfunction consistent with the diagnosis of transplantation failure due to acute/chronic active T-Cell mediated rejection (TCMR) and/or active/chronic active antibody-mediated rejection (ABMR) according to Banff 2017 criteria., Among patients with native kidney, history or presence of any kidney disease other than aHUS, such as: • Known kidney biopsy finding suggestive of underlying disease other than aHUS • Kidney ultrasound finding demonstrating small kidneys suggestive of chronic kidney failure • Known family history and/or genetic diagnosis of non-complement mediated genetic kidney disease (e.g., focal segmental glomerulosclerosis) • Laboratory tests indicative of a kidney disease other than aHUS (eg, Anti-glomerular Basement Membrane (anti-GBM) antibodies, Anti-Neutrophil Cytoplasmic Antibodies (ANCA), Anti-Phospholipase A2 Receptor (anti-PLA2R) antibodies, anti-double stranded DNA (anti-dsDNA) antibodies) • Liver disease or liver injury at screening • Patients with sepsis or active severe systemic bacterial, viral (including COVID-19) or fungal infection., Presence of systemic infections (bacterial, viral, fungal or parasitic) that, in the opinion of the Investigator, confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease., Active infection, or history of recurrent invasive infections, caused by encapsulated bacteria (i.e., meningococcus, pneumococcus), or H. influenzae.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapyMedDRA version: 20.1Level: LLTClassification code 10079841Term: Atypical hemolytic uremic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersatypical hemolytic uremic syndromeEUCTR2020-005186-13-SKovartis Pharma AG50
进行中（未招募）
1 期
Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapyMedDRA version: 20.1Level: LLTClassification code 10079841Term: Atypical hemolytic uremic syndromeSystem Organ Class: 100000004851atypical hemolytic uremic syndromeEUCTR2020-005186-13-SIovartis Pharma AG50
进行中（未招募）
1 期
Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapyatypical hemolytic uremic syndromeEUCTR2020-005186-13-ATovartis Pharma AG50
进行中（未招募）
1 期
Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapyMedDRA version: 20.1Level: LLTClassification code 10079841Term: Atypical hemolytic uremic syndromeSystem Organ Class: 100000004851atypical hemolytic uremic syndromeEUCTR2020-005186-13-CZovartis Pharma AG50
招募中
3 期
Study of LNP023 (iptacopan)to access efficacy and safety in patients who are 18 or more years of age diagnosed with atypical hemolytic uremic syndrome who have never received treatment with complement inhibitorsCTRI/2021/10/037662ovartis Healthcare Pvt Ltd